UPDATE: JPMorgan Downgrades Actus Medical (AFIB) to Neutral

March 19, 2021 2:04 AM EDT
Get Alerts AFIB Hot Sheet
Price: $12.70 -3.79%

Rating Summary:
    1 Buy, 4 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 19 | Down: 18 | New: 47
Trade Now! 
Join SI Premium – FREE
(Updated - March 19, 2021 4:58 AM EDT)

JPMorgan analyst Robbie Marcus downgraded Actus Medical (NASDAQ: AFIB) from Overweight to Neutral with a price target of $19.00 (from $39.00).

The analyst comments "With a revolutionary new way of mapping arrhythmias, we believe Acutus is well-positioned to penetrate the ~$5.7B global electrophysiology ablation market. While several mapping and ablation options are available, innovation in the space has remained largely stagnant in recent years and current offerings are only able to effectively map simple, stable arrhythmias. Acutus’ novel non-contact technology creates a clear picture of the anatomy of the heart and its electrical propagation patterns at four times the resolution of traditional voltage-based maps, enabling physicians to rapidly visualize complex, unstable arrhythmias. However, the company’s near-term outlook is clouded by recent commercial missteps which have pointed to procedure utilization trends that are not as robust as originally anticipated. We still feel confident in the long-term opportunity, but until we see more proof of execution on the commercial front, we assign a neutral rating to AFIB shares."

For an analyst ratings summary and ratings history on Actus Medical click here. For more ratings news on Actus Medical click here.

Shares of Actus Medical closed at $16.83 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change, Downgrades

Related Entities

JPMorgan